UBS Maintains a 'Buy' on Par Pharmaceutical (PRX); Comments From Conference Call
Tweet Send to a FriendGet Alerts PRX Hot Sheet
Price: $49.98 --0%
Rating Summary:
2 Buy, 8 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 12 | New: 30
Rating Summary:
2 Buy, 8 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 12 | New: 30
Trade PRX Now!
UBS maintains a 'Buy' on Par Pharmaceutical (NYSE: PRX) price target raised from $42 to $48.
Analyst, Ami Fadia's Conference Call highlights: (1) Combined R&D efforts from legacy Par, Anchen and Edict teams have enabled Par to track ahead of its goal of 13-17 filings per year; (2) Mgt. expects ~10-14 new launches in the coming qtrs; (3) Base generic business saw minimum erosion in the quarter with a slight GM expansion; (4) 1Q R&D included $10M for the Dexilant deal and a $2M write down on a pipeline product; (5) While SG&A was light in 1Q, mgt. indicated that it is on track to meet full yr guidance of ~$180M; (6) Management remains confident in its Lovaza application/ court case and is ready for a launch."
UBS adjusts FY12 EPS estimate from $4.03 to $3.96.
For an analyst ratings summary and ratings history on Par Pharmaceutical click here. For more ratings news on Par Pharmaceutical click here.
Shares of Par Pharmaceutical closed at $42.08 yesterday, with a 52 week range of $24.85-$42.80.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, Ami Fadia's Conference Call highlights: (1) Combined R&D efforts from legacy Par, Anchen and Edict teams have enabled Par to track ahead of its goal of 13-17 filings per year; (2) Mgt. expects ~10-14 new launches in the coming qtrs; (3) Base generic business saw minimum erosion in the quarter with a slight GM expansion; (4) 1Q R&D included $10M for the Dexilant deal and a $2M write down on a pipeline product; (5) While SG&A was light in 1Q, mgt. indicated that it is on track to meet full yr guidance of ~$180M; (6) Management remains confident in its Lovaza application/ court case and is ready for a launch."
UBS adjusts FY12 EPS estimate from $4.03 to $3.96.
For an analyst ratings summary and ratings history on Par Pharmaceutical click here. For more ratings news on Par Pharmaceutical click here.
Shares of Par Pharmaceutical closed at $42.08 yesterday, with a 52 week range of $24.85-$42.80.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Morgan Stanley Maintains Bullish Stance on Walter Energy (WLT)
- Wells Fargo Cuts Comerica (CMA) and First Horizon National (FHN) to Underperform
- Nokia (NOK) Could See Downside as Siemens Exits NSN Joint-Venture - Goldman
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT ChangeRelated Entities
UBS
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
